Candida albicans antigen
PreclinicalBiologic
Candida albicans antigen is one of 37 biologic programs targeting Alopecia Areata. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
113 competitors in Alopecia Areata
#DrugCompanyPhaseTrials
1Opzelura
PfizerPhase 3
Olumiant
Eli LillyPhase 3
Rinvoq
AbbViePhase 3
PF-06651600
PfizerPhase 3
Jaktinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Velsipity
PfizerPhase 2
Jakafi
IncytePhase 2
Cosentyx
NovartisPhase 2
SHR0302
RReistone Biopharma Company Limited
Phase 3
IL2
AAssistance Publique - Hôpitaux de Paris
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Candida albicans antigen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Michigan